Oncology-focused biotech company Blaze Bioscience today released clinical data from the Phase 1 study of its Tumor Paint BLZ-100 in pediatric brain cancer patients, touting that the agent was well tolerated.
Data from the study was presented at the 4th Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference in New York.
Read the whole story at our sister site, Drug Delivery Business
The post Blaze Bioscience touts Phase 1 data from pediatric oncology Tumor Paint BLZ-100 study appeared first on MassDevice.
from MassDevice http://ift.tt/2suusbC
Cap comentari:
Publica un comentari a l'entrada